Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CT-P59

- PMLiVE

EMA launches rolling review of J&J’s COVID-19 vaccine

Vaccine entered phase 3 testing in September

- PMLiVE

Novavax moves closer toward launch of US phase 3 COVID-19 vaccine trial

Company also completes enrolment in UK-based phase 3 trial

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine gets first approval from UK

The UK has already signed a supply deal for 40 million doses

- PMLiVE

Joint COVID-19 trial begins testing drugs from Amgen, UCB and Takeda

Trial will test therapeutic candidates in hospitalised COVID-19 patients

- PMLiVE

Moderna eyes COVID-19 vaccine approval in the US and the EU

Updated analysis demonstrates efficacy of 94.1%

- PMLiVE

AZ, Oxford University face more scrutiny over COVID-19 vaccine data

WHO’s immunisations director says ‘more than a press release’ is needed

- PMLiVE

COVID-19 infections in England drop by 30% amid national lockdown

Observations come from REACT study led by Imperial College London and Ipsos MORI

- PMLiVE

Moderna and UK sign agreement for additional doses of COVID-19 vaccine

The UK has secured another two million doses on top of previously agreed five million doses

- PMLiVE

The important role of CROs in shaping the future of clinical research across Europe

Looking at the impact of COVID-19 on clinical research activities

- PMLiVE

Be careful what you wish for

Ten months into this pandemic, it seems a lot of people are hoping for some strange things

Environmental impact of in-person vs. virtual meetings

Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...

Impetus Digital

- PMLiVE

Russia says its Sputnik V COVID-19 vaccine is 91.4% effective

Preliminary data demonstrates efficacy of 95% after 42 days

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links